Share Price:

APNASPENAspen Pharmacare Hldgs21798-52 (-0.24%)

Aspen is in a closed period from 1 January until the publication of our interim results on the JSE SENS platform to be released on 4 March 2024.

Statement in response to press reports of 14 and 15 April 2017

In reference to the articles reported in the European press on 14 and 15 April 2017, Aspen Pharmacare Holdings Limited (“Aspen”) has the following comments: Aspen has clearly demonstrated its commitment to providing quality medicines affordably over many years. The supply of the oncology products in question is no exception. Aspen’s status as a responsible… Continue reading Statement in response to press reports of 14 and 15 April 2017

Honouring Ahmed M Kathrada

This morning we wake up to the news, that one of the country’s foremost leaders, a true son of the African soil, Ahmed Mohammed Kathrada, Uncle Kathy, had departed our world. Uncle Kathy, as he was and will continue to be affectionately known to us at Aspen, was one of our country’s key architects of… Continue reading Honouring Ahmed M Kathrada

Aspen’s half-year revenue increases 13% to R19.8 billion

Johannesburg – JSE Limited listed Aspen Pharmacare Holdings Limited (APN), a leading pharmaceutical company in the southern hemisphere, has announced favourable results for the six months ended 31 December 2016. Stephen Saad, Aspen Group Chief Executive said, “The Group has transformed into a global multinational organisation focused on therapeutic specialties over the past few years.… Continue reading Aspen’s half-year revenue increases 13% to R19.8 billion

Closed Period

Aspen is in a closed period from 1 January until the publication of our interim results on the JSE SENS platform scheduled to be released on 1 March 2023.

The live presentation will take place in Cape Town at 08h30 on 2 March 2023.